Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?
Is CYTK a good stock to buy? We came across a bullish thesis on Cytokinetics, Incorporated on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CYTK.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 4,999,999 | $425,949,915 | +50% | 3.82% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,253,649 | $191,988,358 | +36% | 0.45% |
| 3. | Integral Health Asset Management Bhagwan Jay Rao | 1,600,000 | $136,304,000 | 5.38% | |
| 4. | Point72 Asset Management Steve Cohen | 1,587,712 | $135,257,185 | +154% | 0.15% |
| 5. | 1,530,000 | $130,340,700 | -10% | 1.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | $51,426.60 | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | $80,934.59 | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | $473,885.06 | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | $571,880.05 | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | $141,282.00 | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.48 | 5,000 | $357,400.00 | 10,784 | 2026-09-01 | Filing | |
| $70.24 | 10,000 | $702,400.00 | 58,555 | 2026-08-31 | Filing | |
| $70.24 | 7,500 | $526,800.00 | 377,820 | 2026-08-31 | Filing | |
| $75.82 | 3,500 | $265,370.00 | 153,902 | 2026-08-18 | Filing | |
| $76.76 | 7,500 | $575,700.00 | 377,820 | 2026-08-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,094,362 | $1,711,838,738 | 0.03% | |
| 2. | 6,931,770 | $590,517,486 | 0.1% | |
| 3. | 6,711,799 | $571,778,157 | 0.03% | |
| 4. | 6,494,233 | $553,243,709 | 0.02% | |
| 5. | 6,117,515 | $521,151,103 | 0.01% |
News See All
10 Most Promising Mid-Cap Stocks to Buy According to Analysts
In this article, we will discuss the 10 Most Promising Mid-Cap Stocks to Buy According to Analysts.
Citi Calls Cytokinetics, Incorporated (CYTK) a "Top Pick" Among Small-to-Mid Cap Biotech Stocks
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the best momentum stocks to buy according to analysts.
10 Best Momentum Stocks to Buy According to Analysts
In this article, we will look at the 10 Best Momentum Stocks to Buy According to Analysts.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2026 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2026 Earnings Call Transcript May 5, 2026Cytokinetics, Incorporated reports earnings inline with expectations.
10 Stocks Turning Heads With Double-Digit Gains
Ten stocks soared higher on Tuesday, boasting double-digit gains as investors took heart from a flurry of strong corporate earnings for the first quarter of the year.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript February 24, 2026Cytokinetics, Incorporated misses on earnings expectations.
Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space
Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B.
10 Best Debt-Free Mid-Cap Stocks to Buy According to Hedge Funds
In this article, we’ll look at the 10 Best Debt-Free Mid-Cap Stocks to Buy According to Hedge Funds. Mid-cap stocks are poised for an impressive run heading into the US midterm election.
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth
Cytokinetics, Incorporated (NASDAQ:CYTK) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.
Hedge Fund Resource Center